Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971400 | 0.92 | NPY5R (0.72) | NPY5RALDH1A1KMT2AMEN1POLB | |
| SCHEMBL7973349 | 0.82 | NPY5R (0.63) | NPY5RALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3851560 | 0.81 | MEN1 (0.80) | ALDH1A1KMT2AMEN1CYP2C9MAPT | |
| SCHEMBL7960267 | 0.81 | HDAC3 (0.73) | NPY5RKMT2AMEN1POLB | |
| SCHEMBL29877086 | 0.81 | HDAC3 (0.73) | NPY5RKMT2AMEN1POLB | |
| SCHEMBL28745571 | 0.79 | NPY5R (0.66) | NPY5RALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL3853060 | 0.79 | ALDH1A1 (1.00) | NPY5RALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL7699912 | 0.78 | NPY5R (0.60) | NPY5RALDH1A1KMT2AMEN1POLB | |
| SCHEMBL7700849 | 0.77 | ALDH1A1 (0.72) | NPY5RALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL3851236 | 0.77 | GBA1 (0.79) | NPY5RALDH1A1KMT2AMEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | NPY5R 4392/4885ALDH1A1 1804/4885KMT2A 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.